N@N

Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations

_{//health-fitness.news-articles.net/content/2009/ .. nt-of-vice-president-of-clinical-operations.html}
^{Published in Health and Fitness on Thursday, June 18th 2009 at 10:39 GMT, Last Modified on 2009-06-18 10:39:48 by Market Wire}  

 TORONTO, June 18 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce that Ms. Laura Agensky has been appointed Vice-President of Clinical Operations. Since joining Transition in 2001, Ms. Agensky has managed the execution of all the Company's clinical trials across a diverse set of disease indications including Alzheimer's disease and diabetes. Prior to Transition, she served in multiple clinical development roles at large pharmaceutical, biotechnology and consulting organizations. As Vice-President, Ms. Agensky will continue to lead Transition's clinical operations group. About Transition Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit [ www.transitiontherapeutics.com ]. Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions. %SEDAR: 00015806E 

For further information: on Transition, visit [ www.transitiontherapeutics.com ] or contact: Dr. Tony Cruz, Chief Executive Officer, Transition Therapeutics Inc, Phone: (416) 260-7770, x.223, [ tcruz@transitiontherapeutics.com ]; Elie Farah, Chief Financial Officer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.203, [ efarah@transitiontherapeutics.com ]